News Sentiment

IMUX sentiment intelligence

Immunic Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 68 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 14.77 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 59

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-0.2% over one week, +6.6% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

abrdn discloses 6.05% Immunic (IMUX) stake held for clients

Market Reaction

Balanced read

50/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -0.2% Price digesting
Trend fit Trend active 6.6% over four weeks
Fair value 27.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 61
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 59
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 16
TradingView 10
Market source 6
PR Newswire 5
Proactive 3
simplywall.st 3
ad-hoc-news.de 2
Finviz 2

Event Lens

What the news is about

Classified themes
Market update 42
Earnings 18
Regulatory and legal 3
Deals and strategy 2
Balance sheet 2
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 68
BioCentury Direct company coverage

Immunic tests Nurr1 to push beyond MS’s inflammation ceiling

Immunic Inc. is testing vidofludimus calcium, a Phase III candidate for multiple sclerosis, which combines DHODH inhibition with Nurr1 activation. This approach aims to pair targeted immune modulation with direct neuroprotective effects to slow MS progression, addressing the limi

Tone
Positive 67/100
Event
Market update
Published
27 Jun 2026 00:40
Source
BioCentury
TradingView Direct company coverage

Price to book forward of Immunic, Inc. – MUN:10V

This article provides a financial snippet for Immunic, Inc. (MUN:10V), specifically focusing on its "Price to book forward" metric. The content indicates that the market for this stock is currently closed with no trades. It also lists various data providers for the financial info

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 23:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Immunic, Inc. – MUN:10V

The article discusses the enterprise value to revenue for Immunic, Inc. (MUN:10V), traded on the Munich Stock Exchange. It appears to be a financial data snippet from a trading platform, indicating the market was closed with no trades.

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 22:11
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Immunic, Inc. – NASDAQ:IMUX

This article displays the "Enterprise value to EBITDA forward" for Immunic, Inc. (NASDAQ:IMUX) on TradingView. It appears to be a financial data point without additional analytical text, found within the financial overview section of the company's profile on the platform.

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 09:09
Source
TradingView
Moomoo Direct company coverage

Eqs-News: Immunic to Present Additional Phase

This article announces that Immunic will present additional Phase data, as indicated by the title "Eqs-News: Immunic to Present Additional Phase". However, the full content of the document is missing, making it impossible to provide further details on what data will be presented

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 23:39
Source
Moomoo
TradingView Direct company coverage

Enterprise value to EBIT forward of Immunic, Inc. – NASDAQ:IMUX

This article displays financial data for Immunic, Inc. (IMUX) on TradingView, specifically focusing on its enterprise value to EBIT forward ratio. The content seems to be a snapshot from a financial data platform, providing this metric for the pharmaceutical company.

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 19:41
Source
TradingView
GuruFocus Direct company coverage

Immunic Inc (FRA:10V) Stock Price & 30 Year Financial Data

This article provides comprehensive 30-year financial data for Immunic Inc (FRA:10V), detailing growth rates for revenue, EPS, EBIT, EBITDA, and Free Cash Flow, along with price performance. It also includes key financial metrics such as Market Cap, Enterprise Value, PE Ratio, PB

Tone
Positive 61/100
Event
Earnings
Published
24 Jun 2026 13:09
Source
GuruFocus